Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Baxter
McKinsey
Federal Trade Commission
Mallinckrodt

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GEMZAR

« Back to Dashboard

Clinical Trials for Gemzar

Trial ID Title Status Sponsor Phase Summary
NCT00002998 Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
NCT00002998 Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
NCT00003182 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status Hope Cancer Institute, Inc. Phase 1/Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of cisplatin and gemcitabine in treating patients with advanced squamous cell cancer of the head and neck that cannot be surgically removed.
NCT00003925 Combination Chemotherapy In Treating Patients With Advanced Cancer Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine, fluorouracil-uracil and leucovorin in treating patients who have advanced cancer that has not responded to previous therapy.
NCT00003925 Combination Chemotherapy In Treating Patients With Advanced Cancer Completed Barbara Ann Karmanos Cancer Institute Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine, fluorouracil-uracil and leucovorin in treating patients who have advanced cancer that has not responded to previous therapy.
NCT00004063 Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer Unknown status The University of Texas Health Science Center, Houston Phase 1/Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy and interferon alfa may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of cisplatin, gemcitabine, interferon alfa, and whole-body hyperthermia and how well they work in treating patients with metastatic, recurrent, or refractory cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gemzar

Condition Name

Condition Name for Gemzar
Intervention Trials
Pancreatic Cancer 26
Pancreatic Neoplasms 13
Breast Cancer 10
Metastatic Pancreatic Cancer 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gemzar
Intervention Trials
Pancreatic Neoplasms 60
Lung Neoplasms 22
Carcinoma, Non-Small-Cell Lung 22
Adenocarcinoma 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gemzar

Trials by Country

Trials by Country for Gemzar
Location Trials
United States 516
Italy 58
Germany 30
United Kingdom 25
Australia 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gemzar
Location Trials
Texas 36
Florida 27
New York 24
Minnesota 23
Pennsylvania 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gemzar

Clinical Trial Phase

Clinical Trial Phase for Gemzar
Clinical Trial Phase Trials
Phase 4 3
Phase 3 21
Phase 2/Phase 3 3
[disabled in preview] 145
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gemzar
Clinical Trial Phase Trials
Completed 68
Recruiting 44
Terminated 17
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gemzar

Sponsor Name

Sponsor Name for Gemzar
Sponsor Trials
Eli Lilly and Company 24
National Cancer Institute (NCI) 20
Celgene Corporation 9
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gemzar
Sponsor Trials
Other 177
Industry 113
NIH 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Julphar
Healthtrust
Fish and Richardson
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.